A randomized, double-blind, cross-over study comparing a levosulpiride-based and a metoclopramide-based combination in the prevention of promece-cytabom-induced emesis

R. Sabbatini, M. Federico, L. Baldini, F. Barbieri, M. T. Maiolo, V. Silingardi

Research output: Contribution to journalArticle

Abstract

Background. To test two different antiemetic regimens for preventing nausea and vomiting in patients with non-Hodgkin's lymphoma (NHL) undergoing systemic chemotherapy (CT) with ProMECE-CytaBOM (P-C). Patients and Methods. Twenty consecutive untreated adult outpatients with histologically confirmed NHL and scheduled to receive P-C chemotherapy were registered in a randomized, double-blind, cross-over study to compare the antiemetic efficacy of a levosulpiride (LS)-based and metoclopramide (MTC)-based regimen. Results. Complete protection from vomiting was recorded in 93% (62/67) of courses with the LS-regimen and in 89% (62/70) with the MTC-regimen (p = 0.428). No nausea was observed in 84% (56/67) of courses with the LS-regimen and in 74% (52/70) with the MTC-regimen (p = 0.183). No differences prevention of emesis were recorded when patients crossed to the other regimen. Both regimens were well tolerated; however, on day 8 of chemotherapy, when both antiemetic regimens were administered at a higher dose, the LS-based combination showed significantly lower toxicity (p = 0.035). Conclusions. ProMECE-CytaBOM-induced emesis can be prevented in most cases with appropriate, specifically designed antiemetic therapy. Both the LS- and MTC-based combinations resulted in a high percentage of complete protection from emesis, but the higher incidence of side effects observed with MTC makes the LS-based regimen preferable for patients receiving P-C chemotherapy.

Original languageEnglish
Pages (from-to)416-420
Number of pages5
JournalHaematologica
Volume80
Issue number5
Publication statusPublished - 1995

Fingerprint

Metoclopramide
Cross-Over Studies
Vomiting
Antiemetics
Drug Therapy
Non-Hodgkin's Lymphoma
Nausea
levosulpiride
Outpatients
Incidence

Keywords

  • Emesis
  • Levosulpiride
  • Metoclopramide
  • Non-Hodgkin's lymphoma
  • ProMECE-CytaBOM

ASJC Scopus subject areas

  • Hematology

Cite this

A randomized, double-blind, cross-over study comparing a levosulpiride-based and a metoclopramide-based combination in the prevention of promece-cytabom-induced emesis. / Sabbatini, R.; Federico, M.; Baldini, L.; Barbieri, F.; Maiolo, M. T.; Silingardi, V.

In: Haematologica, Vol. 80, No. 5, 1995, p. 416-420.

Research output: Contribution to journalArticle

@article{8bc031b695d048879987120cc2821213,
title = "A randomized, double-blind, cross-over study comparing a levosulpiride-based and a metoclopramide-based combination in the prevention of promece-cytabom-induced emesis",
abstract = "Background. To test two different antiemetic regimens for preventing nausea and vomiting in patients with non-Hodgkin's lymphoma (NHL) undergoing systemic chemotherapy (CT) with ProMECE-CytaBOM (P-C). Patients and Methods. Twenty consecutive untreated adult outpatients with histologically confirmed NHL and scheduled to receive P-C chemotherapy were registered in a randomized, double-blind, cross-over study to compare the antiemetic efficacy of a levosulpiride (LS)-based and metoclopramide (MTC)-based regimen. Results. Complete protection from vomiting was recorded in 93{\%} (62/67) of courses with the LS-regimen and in 89{\%} (62/70) with the MTC-regimen (p = 0.428). No nausea was observed in 84{\%} (56/67) of courses with the LS-regimen and in 74{\%} (52/70) with the MTC-regimen (p = 0.183). No differences prevention of emesis were recorded when patients crossed to the other regimen. Both regimens were well tolerated; however, on day 8 of chemotherapy, when both antiemetic regimens were administered at a higher dose, the LS-based combination showed significantly lower toxicity (p = 0.035). Conclusions. ProMECE-CytaBOM-induced emesis can be prevented in most cases with appropriate, specifically designed antiemetic therapy. Both the LS- and MTC-based combinations resulted in a high percentage of complete protection from emesis, but the higher incidence of side effects observed with MTC makes the LS-based regimen preferable for patients receiving P-C chemotherapy.",
keywords = "Emesis, Levosulpiride, Metoclopramide, Non-Hodgkin's lymphoma, ProMECE-CytaBOM",
author = "R. Sabbatini and M. Federico and L. Baldini and F. Barbieri and Maiolo, {M. T.} and V. Silingardi",
year = "1995",
language = "English",
volume = "80",
pages = "416--420",
journal = "Haematologica",
issn = "0390-6078",
publisher = "NLM (Medline)",
number = "5",

}

TY - JOUR

T1 - A randomized, double-blind, cross-over study comparing a levosulpiride-based and a metoclopramide-based combination in the prevention of promece-cytabom-induced emesis

AU - Sabbatini, R.

AU - Federico, M.

AU - Baldini, L.

AU - Barbieri, F.

AU - Maiolo, M. T.

AU - Silingardi, V.

PY - 1995

Y1 - 1995

N2 - Background. To test two different antiemetic regimens for preventing nausea and vomiting in patients with non-Hodgkin's lymphoma (NHL) undergoing systemic chemotherapy (CT) with ProMECE-CytaBOM (P-C). Patients and Methods. Twenty consecutive untreated adult outpatients with histologically confirmed NHL and scheduled to receive P-C chemotherapy were registered in a randomized, double-blind, cross-over study to compare the antiemetic efficacy of a levosulpiride (LS)-based and metoclopramide (MTC)-based regimen. Results. Complete protection from vomiting was recorded in 93% (62/67) of courses with the LS-regimen and in 89% (62/70) with the MTC-regimen (p = 0.428). No nausea was observed in 84% (56/67) of courses with the LS-regimen and in 74% (52/70) with the MTC-regimen (p = 0.183). No differences prevention of emesis were recorded when patients crossed to the other regimen. Both regimens were well tolerated; however, on day 8 of chemotherapy, when both antiemetic regimens were administered at a higher dose, the LS-based combination showed significantly lower toxicity (p = 0.035). Conclusions. ProMECE-CytaBOM-induced emesis can be prevented in most cases with appropriate, specifically designed antiemetic therapy. Both the LS- and MTC-based combinations resulted in a high percentage of complete protection from emesis, but the higher incidence of side effects observed with MTC makes the LS-based regimen preferable for patients receiving P-C chemotherapy.

AB - Background. To test two different antiemetic regimens for preventing nausea and vomiting in patients with non-Hodgkin's lymphoma (NHL) undergoing systemic chemotherapy (CT) with ProMECE-CytaBOM (P-C). Patients and Methods. Twenty consecutive untreated adult outpatients with histologically confirmed NHL and scheduled to receive P-C chemotherapy were registered in a randomized, double-blind, cross-over study to compare the antiemetic efficacy of a levosulpiride (LS)-based and metoclopramide (MTC)-based regimen. Results. Complete protection from vomiting was recorded in 93% (62/67) of courses with the LS-regimen and in 89% (62/70) with the MTC-regimen (p = 0.428). No nausea was observed in 84% (56/67) of courses with the LS-regimen and in 74% (52/70) with the MTC-regimen (p = 0.183). No differences prevention of emesis were recorded when patients crossed to the other regimen. Both regimens were well tolerated; however, on day 8 of chemotherapy, when both antiemetic regimens were administered at a higher dose, the LS-based combination showed significantly lower toxicity (p = 0.035). Conclusions. ProMECE-CytaBOM-induced emesis can be prevented in most cases with appropriate, specifically designed antiemetic therapy. Both the LS- and MTC-based combinations resulted in a high percentage of complete protection from emesis, but the higher incidence of side effects observed with MTC makes the LS-based regimen preferable for patients receiving P-C chemotherapy.

KW - Emesis

KW - Levosulpiride

KW - Metoclopramide

KW - Non-Hodgkin's lymphoma

KW - ProMECE-CytaBOM

UR - http://www.scopus.com/inward/record.url?scp=0028783589&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028783589&partnerID=8YFLogxK

M3 - Article

C2 - 8566881

AN - SCOPUS:0028783589

VL - 80

SP - 416

EP - 420

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 5

ER -